

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Kashmiri et al.

Art Unit: 1642

Application No. 09/830,748

Filed: April 30, 2001

For: VARIANTS OF HUMANIZED ANTI-CARCINOMA MAB CC49

Examiner: Larry R. Helms

Date: April 9, 2003

**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on April 9, 2003 as First Class Mail in an envelope addressed to: U.S. PATENT AND TRADEMARK OFFICE, BOX SEQUENCE, P.O. BOX 2327, ARLINGTON, VIRGINIA, 22202-2327.

Susan Alpert Siegel, Ph.D.  
Agent for Applicant

**RECEIVED**

APR 18 2003

TECH CENTER 1600/2900

U.S. PATENTS AND TRADEMARK OFFICE  
BOX SEQUENCE  
P.O. BOX 2327  
ARLINGTON, VIRGINIA 22202-2327

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT**

This amendment is submitted in response to the Office action dated February 12, 2003, for which a one-month period for reply was set, making a response due on or before March 12, 2003. Applicants petition for a one-month extension of time and submit the required fee, making a response due on or before April 12, 2003. Please amend the application as follows:

*In the specification:*Please replace the paragraph at page 13, lines 11-14 with the following:

H-CDR1 of CC49 and 21/28'CL differ at three positions, 31, 32, and 34. However, SDR variants which include a corresponding human residue at positions 32 and 34 demonstrate no antigen binding affinity. Thus, a functional SDR variant should not include a corresponding human residue at either of these positions.

Please replace the paragraph at page 15, lines 11-13 with the following:

H-CDR1 of CC49 and 21/28'CL differ at three positions, 31, 32, and 34. SDR variants which include a corresponding human residue at positions 32 and 34 demonstrate no antigen binding affinity.